Kornimate/medical-research-clean huggingface dataset:
diafert® for embryo selection and fertility improvement

Conditions: Infertility

Summary: prospective, single-center, single-blind, randomized, controlled, two-arm, interventional study.


Eligibility criteria:
inclusion criteria: 1. women at least 18 years old at the time of informed consent. 2. able to understand and voluntarily sign an informed consent form approved by the relevant independent ethics committee (iec) governing the site. 3. first or second fresh assisted reproductive technology (art) cycle attempt (since last successful implantation, if any). 4. eligible for elective set of fresh embryo on day 2/3. elective set is defined as a transfer for which there is more than one embryo in the same morphological ("best") category as that of the selected embryo. exclusion criteria: 1. presence or history of ovarian endometriotic cyst. 2. presence or history of diagnosed severe endometriosis (i.e. stage iv of the revised american fertility society classification for endometriosis). 3. hormonal, functional, anatomical and/or other abnormalities potentially increasing the risk of miscarriage and/or ectopic pregnancy as judged by the investigator and determined by medical history and clinical laboratory. this includes, but is not limited to, uncontrolled diabetes mellitus, uncontrolled thyroid disease, alcoholism, drug abuse, abnormal uterine cavity etc. 4. history of two or more consecutive miscarriages. 5. known history of human immunodeficiency virus, hepatitis c virus and/or hepatitis b virus infection. 6. the subject has other serious or acute conditions that, in the investigator's opinion, would preclude her participation in the study. 7. need for preimplantation genetic diagnosis/screening. 8. use of time-lapse embryo imaging 9. participating in oocyte donation procedure. 10. participation in any interventional drug clinical investigation within 2 months 11. dependency on sponsor or investigator (e.g. co-worker or family member).

Keywords: embryo transfer embryo selection criteria for implantation assisted reproductive technology
promoting resiliency among lymphoma survivors: the 3rp-lymphoma

Conditions: Lymphoma

Summary: the relaxation response resiliency program (3rp) was developed by researchers at the mgh benson-henry institute for mind body medicine; this program has recently been adapted to target the needs of individuals who have completed treatment for lymphoma (3rp-lymphoma).

the relaxation response resiliency program, or 3rp, was developed by researchers at the mgh benson-henry institute for mind body medicine. the 3rp is a group program that-through a variety of mind-body approaches, such as imagery, relaxation, and yoga-seeks to buffer stress and promote psychological resiliency and physical well-being. the 3rp has not yet been carried out with individuals who have recently completed treatment for lymphoma. as such, the investigators have adapted the standard 3rp program to target the specific needs of lymphoma patients who are transitioning off active treatment. the investigators are conducting this study to see if the adapted program, the 3rp-lymphoma, is effective at reducing stress and stress-related symptoms for people who have completed treatment for lymphoma within the past two years. to develop the 3rp-lymphoma, the investigators conducted interviews with patients who had recently completed treatment to learn about their experiences and their preferences for topics they would want to include in a program tailored to their specific needs. the current phase of the feasibility study will examine if the adapted program is feasible, acceptable, and helps promote stress management among lymphoma survivors who are in the early stages of completing cancer treatment.

Eligibility criteria:
inclusion criteria: * aged 18-64 * within 2 years post-treatment completion for lymphoma * english speaking * able and willing to provide informed consent * cancer treatment or follow-up for lymphoma at the mgh cancer center exclusion criteria: * unwilling or unable to participate in the study * unable to speak or read english * is medically, psychiatrically, or otherwise unable to participate (as determined by a physician or study pi) * unwilling or unable to participate in group 3rp sessions delivered via the partners telehealth videoconferencing software * participation in qualitative interview during phase 1 (df/hcc 16-396)

Keywords: lymphoma
pimr and pulmonary vascular disease

Conditions: Pulmonary Hypertension

Summary: the findings from this innovative, first-in-man, prospective pilot study will elucidate the role of pimr and rv-imr in pre-capillary ph. the study cohort will consist of patients with pulmonary pressures ranging from normal (advanced lung disease patients undergoing lung transplant evaluation) to severe ph (pah and cteph patients), and thus will allow for identification of a pimr cutoff. participants will include: 1) advanced lung disease patients undergoing bilateral heart catheterization as part of their pre-lung transplant work-up, and 2) newly referred patients to pah and cteph clinics undergoing bilateral heart catheterization as part of standard of care work-up. all participants will undergo pimr testing, and those with pre-capillary ph will also undergo pulmonary oct and measurement of rv-imr. the study seeks to define the relationship between pimr and ph and to establish the pimr threshold that identifies pulmonary microvascular dysfunction as well as to evaluate the association of pimr and pulmonary vascular remodeling on oct in patients with pre-capillary ph. in addition, the study will assess the relationship between rv-imr and rv pressure overload among patients with pre-capillary ph.


Eligibility criteria:
inclusion criteria: * ≥18 years old * able to provide informed written consent. * patients with 1) advanced lung disease requiring standard-of-care bilateral heart catheterization as part of lung transplant evaluation in whom mpap \< 20 mmhg on rhc, or 2) pah/cteph (i.e. pre-capillary ph) undergoing standard-of-care bilateral heart catheterization as part of their work-up/treatment exclusion criteria: * contraindicated to undergo fluoroscopy and/or coronary angiography (e.g. pregnancy) * chronic kidney disease (serum creatinine ≥ 2.0 mg/dl)

Keywords: pulmonary hypertension pulmonary arterial hypertension index of microcirculatory resistance chronic thromboembolic disease pulmonary index of microcirculatory resistance
community awareness resources and education - project 1

Conditions: Cervical Cancer

Summary: to increase early detection of cervical cancer by increasing the proportion of appalachian women, age 18 and older, who receive pap smears at appropriate intervals and return for follow-up care when necessary.

the overall goal of project 1 is to increase early detection of cervical cancer by increasing the proportion of appalachian women, age 18 and older, who receive pap smears at appropriate intervals and return for follow-up care when necessary. the project was implemented in appalachian ohio, a mainly rural and underserved area with a population comprised of 1.5 million adults, aged 18 and older, and used community-based participatory research (cbpr) and community relationships already established in the area by center investigators.

Eligibility criteria:
inclusion criteria: * women age 18 and older * who have visited participating clinics during the last two years and * who consider themselves to be a current patient of that clinic exclusion criteria: * not a resident of the selected ohio appalachia county * under the age of 18
study of the relationship between calcium levels and intact parathyroid hormone (ipth) in adults with repaired or palliated conotruncal cardiac defects

Conditions: Hypoparathyroidism; Tetralogy of Fallot; Pulmonary Valve Stenosis; Conotruncal Cardiac Defects; Heart Defects, Congenital; Pulmonary Atresia

Summary: objectives: i. identify latent hypoparathyroidism in normocalcemic adult survivors with repaired conotruncal cardiac defects, by evaluating parathyroid gland secretory function after induced hypocalcemia. ii. determine the relationship of parathyroid hormone secretion to microdeletions in the same region of chromosome 22q11 as found in patients with digeorge anomaly.

protocol outline: patients are given sodium citrate over a 2 hour infusion on day 1. blood is drawn at times -30, -15, 0, and every 10 minutes thereafter during the infusion. on day 2, patients are given calcium gluconate over a 2 hour infusion. blood is drawn at times -30, -15, 0, and every 10 minutes thereafter during the infusion.

Eligibility criteria:
* diagnostically shown repaired or palliated conotruncal cardiac defects, including tetralogy of fallot with pulmonary stenosis or pulmonary atresia, truncus arteriosus, or interrupted aortic arch type b

Keywords: digeorge syndrome cardiovascular and respiratory diseases conotruncal cardiac defects endocrine disorders genetic diseases and dysmorphic syndromes hypoparathyroidism pulmonary valve stenosis rare disease tetralogy of fallot
hbet for pain and sleep feasibility

Conditions: Pain, Chronic; Sleep Disturbance

Summary: long-term pain affects one-third of the united kingdom population and can be very disabling. people experiencing long-term pain often suffer from disturbed sleep because of their pain symptoms, and disturbed sleep can then make their pain symptoms worse. managing long-term pain is also very costly to the national health service. the most common treatment is prescribed medicines, but these do not always work and can have serious side-effects for some patients. the investigators have been developing an alternative approach for treating long-term pain. this approach uses simple non-invasive tools to promote some kinds of brain activity over others. it involves patients using headphones to listen to some specific sounds, or a headset with lights flashing at particular frequencies. the studies undertaken so far seem to show that doing this can change how the brain responds to pain. it potentially offers an inexpensive yet effective way of reducing pain and improving sleep for patients with long-term pain. there are a few small studies that support this approach and more work is needed. the next step is to find out whether these tools can be reliably used in home settings, how people feel about using this approach, and to gather information to design a larger trial of this technology. therefore the aim of this study is to test the suitability and acceptability of these home-based tools with individuals with long-term pain. up to 30 participants with long-term pain and pain-related sleep disturbance will use the tools for at least 20 minutes at bed time every day for 4 weeks. the investigators will interview them to ask about their experiences of using the tools, and their feedback and suggestions on how the approach should be developed. the investigators will measure changes in the nature of participants' pain, sleep, fatigue and mood. these findings will inform the planning and design of a future much larger study to test this technology. the investigators will make sure that findings from this study are shared widely within the national health service and beyond among patient groups, professionals, charities, specialist centres and commissioners.


Eligibility criteria:
inclusion criteria: * chronic non-cancer pain (recurring pain ≥ 3 months duration) * having nocturnal pain (nrs 0-10 worst pain ≥ 4) * self-reported sleep difﬁculties (trouble falling asleep, difﬁculty staying asleep, waking up too early, or waking up unrefreshed) 3 or more nights per week during the past month exclusion criteria: * planned intervention (injection/ surgery/ new oral medications for pain or sleep) during the 4-week hbet use period * seizure disorder * photosensitivity * hearing or sight problems causing inability to use hbet * cognitive problems or dementia or mental health disorders causing inability to consent

Keywords: audio-visual stimulation brainwave entrainment
a study to assess efficacy, safety and pharmacokinetics of a tacrolimus new oral formulation (mr4) in bmt recipients

Conditions: Bone Marrow Transplantation; Graft Versus Host Disease; Graft-Vs-Host Disease; Graft-Versus-Host Disease

Summary: a study to assess efficacy, safety and pharmacokinetics of a tacrolimus new oral formulation (mr4) in de novo bone marrow transplant recipients


Eligibility criteria:
inclusion criteria: * bone marrow transplantation patients aged 20-54 except for transplanted from genetically hla matched sibling donor. * the patient had been fully informed. exclusion criteria: * the patient had severe impaired hepatic function. * the patient had impaired renal function. * the patient had existing complication of severe cardiac dysfunction. * the patient had severe impaired pulmonary function.

Keywords: tacrolimus immunosuppression bone marrow transplantation graft versus host disease
return to work - will brief intervention reduce opioid-induced back pain?

Conditions: Opioid Dependence; Low Back Pain; Opioid Use

Summary: background back pain is among the most common cause for sick leave in the working population and is the main cause of years lived with disability globally. in norway, about 30% report to live with chronic pain and women are affected more than men. pharmacological strategies for pain management e.g., opioid medications, is a common treatment method. this is despite clinical guidelines suggesting limiting pharmacological treatment in management of chronic back pain. long-term use of opioids is linked to opioid-induced hyperalgesia, paradoxically. however, it is suggested that rna sequencing (seq.) profiling may identify individuals that are at risk of opioid-induced hyperalgesia. to help reduce medication intake brief intervention (bi), a method for discontinuing long-term medication use, has shown to be successful. in this pilot rct the investigators aim to investigate the feasibility of a full scale rct and observational study using bi on opioid-using patients with back pain and concurrently study if the response can be predicted by rna seq. method ten outpatients aged 18-67 years with back pain will be recruited from the orthopaedic department at akershus university hospital. inclusion criteria includes daily use of opioids for more than two weeks consecutively, and sufficient language (norwegian) skills. exclusion criteria includes severe medical or surgical condition such as cauda equina syndrome, rheumatic disease, psychiatric disease, or recent surgery. the patients will be randomised into two groups (5+5) where one group receives the bi and the other gets treatment as usual. data collection will be conducted at three-time points; baseline, four weeks follow-up and three months follow-up (end of trial). the primary outcome for this pilot rct is to test feasibility and estimate effect size for a later full-scale study. secondary outcomes include subjective and objective findings from the data collection. results primary results concerning feasibility are mainly qualitative and will be presented as such. secondary results including demographic information as well as tentative effect size, patient reported outcomes such as pain intensity, anxiety, depression, quality of life, psychosocial stressors in the workplace and the rna seq will be presented descriptively. conclusion the results from this pilot study will assist in constructing the optimal design for a full-scale rct.


Eligibility criteria:
inclusion criteria: * age 18-67 years, admitted from their gp to ahus due to back pain, * daily use of opioids such as ≥ 30 mg codeine or ≥ 45 mg tramadol or ≥ 3 mg oxycodone or other opioids corresponding to a morphine equivalent dose ≥ 10-20 mg exclusion criteria: * cauda equina syndrome * recent surgery (within 1 month) * pregnancy * psychiatric disease * rheumatic disease * diabetic polyneuropathy * cancer * insufficient proficiency in the norwegian language * no remaining work potential and/or permanent sick pension.
study of a probiotic strain to prevent mastitis and to eradicate gbs colonization

Conditions: Mastitis

Summary: in previous studies, the investigators have seen that carefully-selected lactobacillus strains are a good alternative to antibiotics for the treatment of lactational mastitis. the objective of this new study is to check if they can also have a preventive role when administered to women with a history of mastitis with one or more previous infants. since the investigators have also realized that peripartum antibiotherapy (mainly gbs-targeting intrapartum prophylaxis)is a predisposing factor for mastitis (because of the selection of resistant bacteria), the investigators would also like to test if administration of the strains to gbs-colonized pregnant women may lead to gbs eradication. therefore, a mastitis-predisposing factor would de avoid.


Eligibility criteria:
inclusion criteria: * normal pregnancy * healthy women * lactational mastitis in, at least, a previous lactation period * no symptomatic vaginal infections exclusion criteria: * any kind of health problems related to pregnancy * symptomatic vaginal infections * allergy to cow's milk protein * intolerance to lactose * antibiotic treatment

Keywords: probiotic lactobacillus salivarius mastitis prevention group b streptococci intrapartum prophylaxis
performance of the paragit sleeve to measure and monitor motor symptoms in patients with parkinson's disease

Conditions: Parkinson Disease

Summary: this investigation is undertaken to: * evaluate the accuracy and reliability of the device in measuring and recording motor symptoms associated with parkinson's disease (pd), and * to assess the safety and tolerability of the device in patients with pd.


Eligibility criteria:
inclusion criteria: 1. parkinson disease: clinically diagnosed 2. age ≥ 50 (not in the childbearing aged as defined by statistics denmark, 15-49) 3. experiencing at least two of following symptoms and/or side effect on a daily basis: * rigidity * tremor * bradykinesia * dyskinesia (treatment side effect) 4. provision of informed consent, i.e., the subject must be able to: * read and understand the patient information and consent form * sign the patient information and consent form. exclusion criteria: 1. known allergy/hypersensitivity to any material in direct contact with the skin (stainless steel, silicone and polyester) 2. mmse \<24 3. other neurological diseases
clinical and molecular evaluation of childern with familial meditterranean fever and their siblings

Conditions: Familial Mediterranean Fever

Summary: familial mediterranean fever (fmf ,recurrent polyserositis ,periodic disease) is an autosomal recessive auto inflammatory disease which primarily affect population surrounding the mediterranean basin (arabs , turks ,armenians, jews ).despite its striking symptoms pattern fmf was first described as distinct entity only in 1945. it is characterized by recurrent attacks of fever , peritonitis ,pleurisy , arthritis , or erysipelas like skin disease. the most dangerous complication of this disease is secondary amyloidosis . fmf diagnosis is mainly clinical, and the genetic testing is indicated to support it . uncommonly, amyloidosis may develop in individuals carrying two familial mediterranean fever gene (mefv ) mutations without overt clinical symptoms of fmf, a condition designated as phenotype ii. furthermore, two mefv mutations may be harbored without signs or symptoms of fmf nor of reactive amyloidosis. this 'silent' homozygous or compound heterozygote state is termed phenotype iii.


Eligibility criteria:
inclusion criteria: a- all children diagnosed as fmf according to tel hashomer criteria aged below 18 years: the presence of at least 2 of the following 5 criteria after exclusion of other causes can diagnose fmf with high sensitivity: 1. fever axillary temperature of \>38ᵒc, 6-72 h of duration, ≥3 attacks 2. abdominal pain 6-72 h of duration ≥3 attacks 3. chest pain 6-72 h duration≥ 3 attacks 4. arthritis 6-72 h duration ≥3 attacks, oligoarthritis 5. family history of fmf\*(11) b-sisters and brothers of a child with fmf with clinical or subclinical manifestation of fmf. exclusion criteria: 1. children with other auto inflammatory diseases, or with other diseases. 2. persons above 18 years old.
a study to evaluate the safety, tolerability, and immunogenicity of v116 in pneumococcal vaccine-experienced adults (v116-006, stride-6)

Conditions: Pneumonia, Pneumococcal

Summary: this a study of v116 in adults ≥50 years of age who previously received a pneumococcal vaccination ≥1 year before enrollment. the primary objectives of this study are to evaluate the safety, tolerability, and immunogenicity of v116.

participants will be randomized to 1 of 3 cohorts depending upon prior vaccinations. prior vaccinations by cohort include: ppsv23 (pneumococcal vaccine, polyvalent \[23-valent\], pneumovax™23) for cohort 1; pcv13 (pneumococcal 13-valent conjugate vaccine; prevnar 13™) for cohort 2; pcv15 (pneumococcal 15-valent conjugate vaccine; vaxneuvance™), pcv20 (pneumococcal 20-valent conjugate vaccine; prevnar 20™), pcv13+ppsv23, pcv15+ppsv23, or ppsv23+pcv13 for cohort 3.

Eligibility criteria:
the main inclusion and exclusion criteria include but are not limited to the following: inclusion criteria: * has received pneumococcal vaccine \>= 1 year before enrollment (pcv13, pcv15, pcv20, ppsv23, pcv13+ppsv23, ppsv23+pcv13, or pcv15+ppsv23). exclusion criteria: * has a history of invasive pneumococcal disease (ipd). * has a known hypersensitivity to any component of v116, pcv15, pcv20, or ppsv23, including diphtheria toxoid. * has a known or suspected impairment of immunological function including, but not limited to, a history of congenital or acquired immunodeficiency, documented human immunodeficiency virus (hiv) infection, functional or anatomic asplenia, or history of autoimmune disease. * has a coagulation disorder contraindicating intramuscular vaccination. * has a known malignancy that is progressing or has required active treatment. * has received ppsv23 followed by either pcv15 or pcv20. * received systemic corticosteroids (prednisone equivalent of ≥20 mg/day). * is currently receiving immunosuppressive therapy, including chemotherapeutic agents or other immunotherapies/immunomodulators used to treat cancer or other conditions, and interventions associated with organ or bone marrow transplantation, or autoimmune disease. * has received any non-live vaccine ≤14 days before receipt of study vaccine or is scheduled to receive any non-live vaccine ≤30 days after receipt of any study vaccine. * has received any live virus vaccine ≤30 days before receipt of study vaccine or is scheduled to receive any live virus vaccine ≤30 days after receipt of study vaccine. * has received a blood transfusion or blood products, including immunoglobulin ≤6 months before receipt of study vaccine or is scheduled to receive a blood transfusion or blood product until the day 30 post-vaccination blood draw is complete.